Switching from Warfarin to Apixaban Protocol
Discontinue warfarin and start apixaban when the INR falls below 2.0 1. This is the FDA-approved and guideline-recommended approach that minimizes both thrombotic and bleeding risks during the transition.
Step-by-Step Transition Protocol
1. Stop Warfarin
- Discontinue warfarin immediately when you decide to make the switch
- Do not wait for INR to drop before stopping warfarin
2. Monitor INR
- Check INR within 2-3 days after stopping warfarin
- Continue checking INR every 1-2 days until it drops below 2.0
- Start apixaban only when INR < 2.0 1
3. Initiate Apixaban at Appropriate Dose
Standard dose: 5 mg twice daily for most patients
Reduced dose: 2.5 mg twice daily if patient has at least 2 of the following 3 criteria 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
4. No Bridging Required
- Bridging anticoagulation with heparin or low molecular weight heparin is not necessary during the transition period 1
- The brief period between stopping warfarin and starting apixaban (typically 2-5 days) carries acceptable thrombotic risk
Critical Timing Considerations
The INR threshold of 2.0 is crucial because:
- Starting apixaban while INR is elevated (>2.0) increases bleeding risk due to overlapping anticoagulant effects
- Warfarin's effect on INR can persist for 3-5 days after discontinuation depending on the patient's metabolism
- Most patients will reach INR <2.0 within 3-5 days of stopping warfarin
Important Caveats and Pitfalls
Drug Interactions
If the patient is on combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir):
- Reduce apixaban dose by 50% (from 5 mg to 2.5 mg twice daily)
- Avoid apixaban entirely if patient already requires 2.5 mg twice daily for other reasons 1
Renal Function
- Apixaban can be used across all levels of renal function, including severe impairment (CrCl 15-30 mL/min) and dialysis 2
- The dose reduction criteria above already account for renal impairment via the creatinine criterion
- Recent evidence suggests apixaban is safe even in severe renal impairment 3
Patient Education
- Emphasize twice-daily dosing (unlike warfarin's once-daily schedule)
- No INR monitoring needed after transition
- Fewer dietary restrictions compared to warfarin
- If a dose is missed, take it as soon as remembered on the same day, but never double up 1
Clinical Outcomes Evidence
Recent real-world data strongly supports this switch. Among patients with atrial fibrillation switching from warfarin to apixaban, there was a lower rate of the composite outcome of ischemic stroke, major bleeding, and death (rate ratio 0.92,95% CI 0.89-0.95) compared to continuing warfarin 4. However, be aware that switching may temporarily increase risk during the first 60 days, followed by risk reduction beyond 60 days 4.
This contrasts with switching to rivaroxaban, which was associated with increased risk (rate ratio 1.08) 4, making apixaban the preferred DOAC when switching from warfarin.
Guideline Support
Both the 2024 ESC 5 and 2023 ACC/AHA 2 guidelines recommend DOACs (including apixaban) over warfarin for stroke prevention in atrial fibrillation, except in patients with mechanical heart valves or mitral stenosis. The guidelines specifically endorse switching from warfarin to DOACs in cases of poor INR control or increased intracranial hemorrhage risk 5.